DeutschNewstral
Article
bizjournals.com on 2019-10-28 18:03
Why this Philadelphia cancer therapy developer is taking a clinical testing path less travelled
Related news
- Philadelphia gene therapy developer, backed by $250M, makes first acquisitionbizjournals.com
- Philadelphia cell therapy developer signs licensing deal with NYU Langone Healthbizjournals.com
- Philadelphia gene therapy startup plans $125M IPObizjournals.com
- Philadelphia cell therapy company closes $100M financingbizjournals.com
- Philadelphia scientific instruments developer raises $5.6Mbizjournals.com
Stockton selling Showboat to Philadelphia developerjournalrecord.com- North Carolina clinical logistics firm opens Philadelphia warehousebizjournals.com
- Philadelphia cell therapy company prices $84M public stock offeringbizjournals.com
- French gene therapy company SparingVision establishes U.S. headquarters in Philadelphiabizjournals.com
- Philadelphia gene therapy company awarded $4.5M from Cystic Fibrosis Foundationbizjournals.com
- Philadelphia gene therapy startup targeting heart disease raises $11Mbizjournals.com
- Philadelphia cell therapy startup launches with $250M in finanicial commitmentsbizjournals.com
- Philadelphia gene therapy company files plans to go publicbizjournals.com
- Philadelphia biotech firm expands gene therapy partnership with Pennbizjournals.com
- Lifestyle IV-therapy concept targets Philadelphia, Montgomery counties for expansionbizjournals.com
- TThe Path Less Travelledtheanchor.ca
- Philadelphia apartment developer eyes big Center City propertiesbizjournals.com
- Nashville developer lands $295M loan for Philadelphia projectbizjournals.com
- TThe Path more travelledtheirishworld.com
- Philadelphia developer drops plans for apartments on The Landingbizjournals.com